Intensifying nationwide environmental enforcement is affecting foreign company supply chain management, compliance, and reporting procedures in China. New rounds of environmental inspections have already led to increased supply chain disruption and, in some cases, factory shutdowns for months. This pervasive nationwide trend has important implications for companies as they approach environmental compliance.
Chinese regulations on tendering and bidding practices published by the Ministry of Finance (MOF) in July are a promising sign for US pharmaceutical and medical device manufacturers that government procurement behavior will be better regulated to guarantee consideration of quality alongside price. However, true improvement for the industry will require regulators to faithfully implement the law and refrain from unofficial practices such as local favoritism, which sometimes plague procurement processes.
Recently announced provincial reimbursement drug lists (PRDLs) provide possible new opportunities for US pharmaceutical companies seeking to expand market reach for their drugs in China. These updated subnational lists largely reflect the national reimbursement drug list (NRDL), which was released by the Ministry of Human Resources and Social Security (MOHRSS) on March 17 for the first time in eight years. However, some PRDLs include potential new openings for drugs that were not among the 300 added to the most recent NRDL update.
Facing ongoing pollution challenges and a push to diversify energy sources, China’s energy planners kicked off 2017 by announcing an array of 13th Five-Year Plans (13FYPs). Offering quantifiable short-term goals for limiting reliance on coal in favor of oil and gas, these plans collectively focus on emissions cuts, renewable energy development, and improved energy industry efficiency, while encouraging technology solutions such as data centers.
The Chinese healthcare sector, which accounted for 6 percent of the country’s GDP in 2016, is expected to capture a 10 percent share in the coming years. Racing to establish a modern system of coverage, services, and products to accommodate the world’s largest population and fastest growing economy, China faces a number of development challenges. As China increasingly makes use of foreign products, services, and expertise to accomplish its reform goals, foreign companies are in a position to advance China’s reform goals in the healthcare sector, if allowed market access.
As the world braces for an expected shift in US climate policy under Trump, China will suddenly be in position to take the lead in the global fight against climate change. This is a complex proposition, as China has proven both its impressive renewable energy development capabilities, as well as its current inability to control pollution.
Seeking to rebuild trust between people and the government, Beijing has revealed plans for a “social credit system” that rates citizens based on their social and financial standing—effectively turning big data into big brother.
Growing public dissatisfaction toward rampant pollution in China is putting pressure on Beijing to craft a national development agenda that more comprehensively takes into account environmental considerations.
Climate change and clean energy issues continue to be a noticeably encouraging point of bilateral cooperation between the US and China.
Facing surmounting challenges, China seeks to revise its environmental trajectory, determined to smoothly and successfully transition from an overdependence on fossil fuels—particularly coal—to an embrace of clean energy.